Skip to main content

Cardio/Pulmonary

RA is associated with a 24‐35% lower risk of type 2 diabetes. Claims data comparison of 449,327 RA, general non‐RA, hypertension, OA, or PsA patients finds a lower risk of T2DM in RA (7/1000PY) and highest w/ HTN (12.3/1000PY) https://t.co/uZn5qaImO9

Dr. John Cush RheumNow ( View Tweet)

Aug 06, 2020

Thromboembolic Risk with Tofacitinib in RA, PsA and UC

Aug 06, 2020

An analysis of the tofacitinib (Xeljanz) drug development program in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ulcerative colitis suggests a low level risk for venous (VTE) and arterial thromboembolism (ATE).  



In the last 2 years, observational data has

Read Article
Analysis of PPI use from the Nurses Health Study shows regular PPI use was associated with increased risk of RA in women, higher with a longer duration of PPI use.

Dr. John Cush RheumNow ( View Tweet)

Aug 05, 2020

Methotrexate Not Associated with Interstitial Lung Disease

Aug 05, 2020

A case-controlled study shows that methotrexate (MTX) use in rheumatoid arthritis (RA) is not associated with interstitial lung disease (ILD) according to a report in the European Respiratory Journal.



Researchers examined the associatioin by comparing 410 RA patients with

Read Article

IL-1 Blockade: A Treatment at Last for Osteoarthritis?

Aug 05, 2020

The interleukin (IL)-1β inhibitor canakinumab (Ilaris) showed promise for preventing the need for hip or knee replacement among patients with osteoarthritis in an exploratory analysis of data from a randomized clinical trial, investigators reported.

Among patients enrolled in CANTOS, the pooled

Read Article

Lovastatin Fails to Lower CRP and Activity in RA

Aug 04, 2020

Ridker and colleagues have shown that statins (3-hydroxy-3-methylglutaryl coenzyme-A (HMG Co-A) reductase inhibitors) are effective at treating hyperlipidaemia and lowering C-reactive protein levels; Aranaow and colleagues have shown that lovastatin, when given to rheumatoid arthritis (RA)

Read Article

Colchicine Benefits COVID-19 Patients

Jul 30, 2020

A proof-of-concept study published in Annals of Rheumatic Disease suggests that colchicine significantly improves COVID-19 outcomes.

Efficacy and safety must be determined in controlled clinical trials.he outbreak of COVID-19 posed the issue of urgently identifying treatment strategies.

Read Article
Important finding of marked lung fibrosis (scarring) after severe #COVID19 in 8 patients https://t.co/Akp6jVXmB9 @TheLancetInfDis (first complete pathologic description of this finding) https://t.co/QCuri3olgs
Eric Topol EricTopol ( View Tweet)
Jul 29, 2020
The RheumNow Podcast is up - COVID-19 Responds to Steroids & TCZ, statin myopathy, Lung Dz in AOSD, TNFi & Liver, IL-23 in Psoriasis.

Dr. John Cush RheumNow ( View Tweet)

Jul 24, 2020
Systematic review of 100 pts with statin-associated myopathy showed mean age 65 yrs, presenting w/ symmetric prox.

Dr. John Cush RheumNow ( View Tweet)

Jul 22, 2020
Retrospective cohort of 147 Adult-Onset Stills Dz pts finds 18 (12.3%) with lung dz (LD) at the diagnosis of AOSD. AOSD-LD were older, w/ more myalgia, LN, pleuritis, ab,dominal pain, more systemic Dz, higher ferritin and more mortality (%39 vs 10%).

Dr. John Cush RheumNow ( View Tweet)

Jul 22, 2020
RheumNow Podcast is Up! Listen to Fauci! Watch it here>> https://t.co/dHq3fP85Ip or Listen to the Podcast>> https://t.co/LdHO7fKUCp

Dr. John Cush RheumNow ( View Tweet)

Jul 17, 2020

Characteristics Underlying Mortal COVID-19 Outcomes

Jul 17, 2020

From January 1, 2020–May 18, 2020, approximately 1.3 million cases of coronavirus disease 2019 (COVID-19) and 83,000 COVID-19–associated deaths were reported in the United States. MMWR reports that COVID-19 mortality is higher in persons with underlying medical conditions and in those aged ≥

Read Article

RheumNow Podcast – LTF – Listen to Fauci (7.17.20)

Jul 17, 2020

Dr. Jack Cush reviews the news, tweets and journal articles from the past week on RheumNow. Let's dig into this week's 14 highlights.

Read Article

HCQ May Help Prevent Fetal Heart Block

Jul 16, 2020

Hydroxychloroquine (HCQ) helped reduce recurrent maternal autoantibody-mediated congenital heart block (CHB) in fetuses, an open-label study suggested.



Anti-SSA/Ro-positive mothers who had had a previous pregnancy complicated by CHB who took HCQ 400 mg daily, starting before

Read Article
Retrospective study of 603 myositis (IIM), 4047 RA and 4061 controls shows IIM has higher risk of CV events (HR 1.38) and MI [HR 1.61] but not CVA [HR 0.92]. The CV risk in IIM was equal to that in RA [HR 1.01].

Dr. John Cush RheumNow ( View Tweet)

Jul 16, 2020
Systematic review of DYSPHAGIA in inflammatory myositis finds it may be an initial or sole symptom. Prevalence in IIM was 36% and higher 56% inclusion body myositis, cancer or NXP2 -associated myositis.

Dr. John Cush RheumNow ( View Tweet)

Jul 16, 2020

Anti-Rheumatic Therapies for COVID-19 Infection

Jul 15, 2020

Since the onset of the COVID-19 pandemic numerous anti-rheumatic therapies have been proposed as being potentially beneficial. The mechanistic effects of these agents, either presumed antiviral, anti-inflammatory and anti-thrombotic effects, may benefit mitigate the damage seen with COVID-19

Read Article

ICYMI: Protective Benefit of Colchicine in COVID-19 Infection

Jul 10, 2020

Colchicine has been advocated as a potential anti-inflammatory intervention in patients with the coronavirus 2 infection and clinical trials have been developed to assess its effect in early COVID-2 infection.  JAMA has published a randomized clinical trial showing that low dose colchicine had

Read Article

ICYMI: COVID-19 and Thrombotic Complications

Jul 08, 2020

Severe and fatal outcomes with coronavirus infection are often the result of the downstream damage that follows the viral infection. Rising high on the list of complications are the hematologic and vascular complications seen in severely affected patients, so much so that many centers are

Read Article
African-Americans with Ank Spondylitis have worse disease compared to whites. Study of 10,990 AS patients shows AA to have high frequency of anterior uveitis, hypertension, diabetes, depression, and heart disease and higher ESR and CRP levels.

Dr. John Cush RheumNow ( View Tweet)

Jul 08, 2020
Case Controlled Study of 482 RA patients with ILD vs 741 RA w/o IL found an inverse relationship Between MTX exposu… https://t.co/ljtaKO8pVZ

Dr. John Cush RheumNow ( View Tweet)

Jul 06, 2020
Study of NSAID use in 7747 patients hospitalized with influenza or influenza pneumonia found NSAID use was not associated with an increase in 30-day intensive care unit admission or death https://t.co/9LmFLeqJD2

Dr. John Cush RheumNow ( View Tweet)

Jul 03, 2020
Pneumonia vaccination of 21461 RA pts in UK Clinical Practice Research Datalink (2000-18) finds 38.2% vaccinated; 44.3% ≥65 years, 66.4% female; 36.5% vaccinated prior to starting csDMARDs, moreso in elderly.

Dr. John Cush RheumNow ( View Tweet)

Jul 03, 2020
Rituximab (RTX)-associated autoimmune disease flare is rare and only seen in 7/185 pts (3.4%); all w/ type II mixed cryoglobulinemia vasculitis.

Dr. John Cush RheumNow ( View Tweet)

Jul 01, 2020
×